Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1991 1
1992 2
1993 1
2005 1
2008 1
2011 1
2012 1
2014 2
2015 1
2017 2
2018 4
2019 3
2020 1
2021 2
2023 1
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.
Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Lancet Reg Health Eur. 2024 Feb 1;38:100847. doi: 10.1016/j.lanepe.2024.100847. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38328413 Free PMC article.
Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.
Fadini GP, Bonora BM, Ghiani M, Anichini R, Melchionda E, Fattor B, Fazion S, Meregalli G, Giaccari A, Avogaro A, Consoli A; GLIMPLES study investigators. Fadini GP, et al. Among authors: fattor b. Diabetes Obes Metab. 2024 Jun;26(6):2390-2400. doi: 10.1111/dom.15554. Epub 2024 Mar 13. Diabetes Obes Metab. 2024. PMID: 38477183
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.
Fadini GP, Longato E, Morieri ML, Bonora E, Consoli A, Fattor B, Rigato M, Turchi F, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Among authors: fattor b. Diabetologia. 2024 Nov;67(11):2585-2597. doi: 10.1007/s00125-024-06251-z. Epub 2024 Aug 23. Diabetologia. 2024. PMID: 39177691 Free PMC article.
Sensory neuropathy in paraneoplastic leucocytosis.
Amor F, Bernardo M, Fattor B, Wiedermann CJ. Amor F, et al. Among authors: fattor b. BMJ Case Rep. 2012 Aug 8;2012:bcr2012006487. doi: 10.1136/bcr-2012-006487. BMJ Case Rep. 2012. PMID: 22878999 Free PMC article.
Continuous subcutaneous insulin infusion in Italy: third national survey.
Bruttomesso D, Laviola L, Lepore G, Bonfanti R, Bozzetto L, Corsi A, Di Blasi V, Girelli A, Grassi G, Iafusco D, Rabbone I, Schiaffini R; Italian Study Group on Diffusion of CSII. Bruttomesso D, et al. Diabetes Technol Ther. 2015 Feb;17(2):96-104. doi: 10.1089/dia.2014.0242. Epub 2014 Dec 5. Diabetes Technol Ther. 2015. PMID: 25479035 Free article.
Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta-analysis of observational studies.
Fadini GP, Bonora BM, Lapolla A, Fattor B, Morpurgo PS, Simioni N, Avogaro A; DARWIN-T2D Network. Fadini GP, et al. Among authors: fattor b. Diabetes Obes Metab. 2019 May;21(5):1255-1260. doi: 10.1111/dom.13623. Epub 2019 Jan 22. Diabetes Obes Metab. 2019. PMID: 30578607 Free PMC article.
26 results